FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 JANUARY 2018

FOR

BRANCASTER PHARMA LIMITED

CONTENTS OF THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 JANUARY 2018

	Page
Company Information	1
Balance Sheet	2
Notes to the Financial Statements	3

BRANCASTER PHARMA LIMITED

COMPANY INFORMATION FOR THE YEAR ENDED 31 JANUARY 2018

DIRECTOR: A J Duckworth

REGISTERED OFFICE: The Office

Heath View Ray Lane Blindley Heath Surrey

RH7 6LH

REGISTERED NUMBER: 08181124 (England and Wales)

ACCOUNTANTS: John Williams and Co

Chartered Accountants

Chart House 2 Effingham Road

Reigate Surrey RH2 7JN

BALANCE SHEET31 JANUARY 2018

	201	18	2017	7
Notes	£	£	£	£
4		2,175		923
5	228,812		108,262	
6	1,173,819		1,333,021	
	6,150,992		3,325,327	
	7,553,623		4,766,610	
7	794,523		755,596	
		6,759,100		4,011,014
		6,761,275		4,011,937
Ŕ		413		185
Ü				4,011,752
		,,		
		1		1
		6,760,861		4,011,751
		6,760,862		4,011,752
	5 6	Notes £ 4 5 228,812 6 1,173,819 6,150,992 7,553,623 7 794,523	4 2,175 5 228,812 6 1,173,819 6,150,992 7,553,623 7 794,523 6,759,100 6,761,275 8 413 6,760,862	Notes £ £ £ £ £

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 January 2018.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 January 2018 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:

- (a) ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
 - preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections
- (b) each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions of Part 15 of the Companies Act 2006 relating to small companies.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director on 26 April 2018 and were signed by:

A J Duckworth - Director

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 JANUARY 2018

1. STATUTORY INFORMATION

Brancaster Pharma Limited is a private company, limited by shares, registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with the provisions of Section 1A "Small Entities" of Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover

Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Computer equipment - 15% on reducing balance

Stocks

Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation

Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Research and development

Expenditure on research and development is written off in the year in which it is incurred.

Foreign currencies

Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

Hire purchase and leasing commitments

Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Page 3 continued...

NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 JANUARY 2018

2. ACCOUNTING POLICIES - continued

Pension costs and other post-retirement benefits

The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 5 (2017 - 4).

4. TANGIBLE FIXED ASSETS

			Computer
			equipment £
	COST		J.C
	At 1 February 2017		1,772
	Additions		1,636
	At 31 January 2018		3,408
	DEPRECIATION		
	At 1 February 2017		849
	Charge for year		384
	At 31 January 2018		1,233
	NET BOOK VALUE		
	At 31 January 2018		<u>2,175</u>
	At 31 January 2017		<u>923</u>
_	070.000		
5.	STOCKS	2010	2017
		2018	2017
	Stocks	£	£
	Stocks	228,812	108,262
6.	DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR		
		2018	2017
		£	£
	Trade debtors	829,172	988,374
	Other debtors	343,647	343,647
	Prepayments	1,000	1,000
		1,173,819	1,333,021
7.	CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR		
7.	CREDITORS: AMOUNTS FALLING DUE WITHIN ONE TEAR	2018	2017
		£	£
	Bank loans and overdrafts	~_	105,956
	Trade creditors	327,318	2,507
	Tax	260,493	331,966
	VAT	194,155	305,030
	Other creditors	12,557	10,137
		794,523	755,596

Page 4 continued...

NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 JANUARY 2018

8. **PROVISIONS FOR LIABILITIES**

TRO VISIONOT OR EMBERITED	2018	2017
	£	£
Deferred tax	<u>413</u>	<u> 185</u>
		Deferred
		tax
		£
Balance at 1 February 2017		185
Accelerated capital allowances		228
Balance at 31 January 2018		413

9. RELATED PARTY DISCLOSURES

During the year the company distributed dividends of £128,500 (2017 - £137,000) to Mr A J Duckworth, a shareholder in the company.

Also during the year the company distributed dividends of £128,500 (2017 - £137,000) to Mrs K M Duckworth, a shareholder in the company.

10. ULTIMATE CONTROLLING PARTY

The company is under the control of its director.

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.